{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-050349","form_type":"8-K","ticker":"CCCC","cik":"0001662579","company_name":"C4 Therapeutics, Inc.","filed_at":"2024-12-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.147478+00:00","generated_at":"2026-05-29T05:40:29.286193+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"C4 Therapeutics presents cemsidomide Phase 1 data: 36% ORR in MM, 44% ORR in PTCL at ASH","bullets":["In MM with dexamethasone, 36% ORR and 45% CBR at 75 µg QD; no dose reductions due to AEs.","In NHL monotherapy, 38% ORR across subtypes; in PTCL, 44% ORR and 19% complete metabolic response rate.","Neutropenia manageable; no discontinuations due to neutropenia; MTD not yet reached.","Next steps: complete Phase 1 dose escalation, initiate combo trials, engage regulators on path.","Data support potential best-in-class IKZF1/3 degrader for MM and NHL."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-050349","json":"https://secwatch.observer/filing/0001628280-24-050349.json","markdown":"https://secwatch.observer/filing/0001628280-24-050349.md","text":"https://secwatch.observer/filing/0001628280-24-050349.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662579/000162828024050349/0001628280-24-050349-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662579/000162828024050349/cccc-20241209.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T05:40:29.286193+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}